Will provide its induced Pluripotent Stem Cell line to Universal Cells for use in its universal donor cell line More: Cell and Gene Therapy Catapult in new stem-cell deal Source: News
read moreSays original Amgen/Sanofi trial jury was not properly instructed More: US court throws out Praluent sales ban Source: News
read moreJust two days after Teva learned Mylan had won an FDA approval for its long-acting Copaxone generic, Mylan’s European partner announced it’d be giving Teva trouble across the pond, too. More: Mylan piles generic Copaxone pain on Teva as partner
read moreOnly days after Sen. Claire McCaskill reached out to drug industry leadership with concerns over Allergan’s tribal licensing deal, she’s moving to shut down the “brazen loophole.” The influential senator has introduced a bill aimed at stopping the practice before
read moreAn appeals court today tossed out a ban on Sanofi and Regeneron’s cholesterol drug Praluent and is giving the partners a second chance to prove they didn’t trample on Amgen patents in its development. More: Court tosses Praluent ban, gives
read moreNovartis is in the very early days of its Kymriah rollout in the U.S., where it will incorporate pay-for-performance pricing on a costly yet promising therapy. But as the drugmaker looks ahead to global approvals, CEO-to-be Vas Narasimhan has to
read more© 1994 - 2026 B.M. Pharmaceuticals